Alpha Teknova, Inc. (TKNO) - 10-K Summary
Business Context and Reporting Period
Company: Alpha Teknova, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Teknova is a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. The company operates two primary product categories: Lab Essentials (research-grade) and Clinical Solutions (GMP-grade). It serves over 3,000 customers globally, including pharmaceutical companies, biotechnology firms, and academic institutions. The company is headquartered in Hollister, California, and is classified as an "emerging growth company" and a "smaller reporting company."
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Revenue | $40,520 | $37,745 |
| Gross Profit | $13,441 | $7,231 |
| Gross Margin | 33.2% | 19.2% |
| Operating Loss | $(16,976) | $(26,146) |
| Net Loss | $(17,259) | $(26,745) |
| Net Loss Per Share (Basic/Diluted) | $(0.32) | $(0.57) |
| Cash and Cash Equivalents | $5,912 | $3,708 |
| Short-Term Investments | $15,426 | $26,688 |
| Working Capital | $27,000 (approx.) | N/A |
| Long-Term Debt (Net) | $13,123 | $9,443 |
Note: 2024 gross margin was impacted by $2.8 million in non-recurring inventory write-downs. Adjusted 2024 gross margin would have been 26.5%.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 7.4% to $40.5 million, driven by growth in both Lab Essentials (7.5% increase) and Clinical Solutions (7.8% increase). International revenue grew 24.4% but remains a small portion (5.6%) of total sales.
- Margin Expansion: Gross profit margin improved significantly from 19.2% to 33.2%. This was primarily due to the absence of the $2.8 million non-recurring inventory charges recorded in 2024, alongside manufacturing efficiency gains.
- Expense Reduction: Total operating expenses decreased 8.9% to $30.4 million. General and Administrative (G&A) expenses dropped 12.2% due to lower stock-based compensation (following a 2024 option repricing) and reduced facility/insurance costs. R&D expenses fell 20.4% due to a workforce reduction completed in early 2024.
- Loss Reduction: Net loss improved by 35.5% to $17.3 million, reflecting the combination of revenue growth and cost containment.
Guidance, Outlook, Risks, and Unusual Items
- Debt and Liquidity: On March 3, 2025, the company entered into a Second Amended and Restated Credit Agreement with MidCap Financial Trust. The facility includes a $23.245 million term loan and a $5.0 million revolver. The agreement includes covenants requiring minimum trailing twelve-month net revenue (e.g., $39.0 million for the period ending Dec 31, 2025) and a minimum cash balance of $8.0 million. The company was in compliance as of year-end.
- Unusual Items:
- 2024 Inventory Charges: The 2024 period included $2.8 million in non-recurring charges for expired and excess inventory write-downs, which distorted year-over-year margin comparisons.
- Loan Exit Fee Adjustment: In 2025, the company recognized a $0.5 million adjustment related to a loan exit fee concurrent with refinancing.
- Workforce Reduction: A reduction of approximately 35 positions occurred in early 2024, resulting in $1.3 million in one-time costs.
- Risks and Contingencies:
- Profitability: The company has a history of operating losses and an accumulated deficit of $135.8 million. Future profitability is not guaranteed.
- Customer Concentration: One distributor customer accounted for 21% of 2025 revenue.
- Supplier Concentration: Two suppliers accounted for 56% of total inventory purchases in 2025.
- Legal: A former employee filed a wage and hour claim in 2023; the company settled for $0.4 million in April 2025.
- Regulatory: While products are currently exempt from FDA regulation as "Research Use Only," there is a risk the FDA could reclassify them, requiring costly approvals.
Investor Verification Checklist
- Covenant Compliance: Verify continued compliance with the $39.0 million minimum revenue and $8.0 million minimum cash covenants under the MidCap credit facility.
- Inventory Valuation: Monitor inventory levels and reserve policies to ensure no recurrence of the significant write-downs seen in 2024.
- Customer Concentration: Assess the stability of the top distributor customer (21% of revenue) and the impact of any potential loss.
- Capital Needs: Evaluate the runway provided by current cash ($5.9M) and short-term investments ($15.4M) against the burn rate, given the company's history of net losses.
- Regulatory Status: Confirm the company's stance on FDA "Research Use Only" exemptions remains unchanged.